目的 探討5-氟尿嘧啶(5-Fu)聯(lián)合甲氨蝶呤治療惡性滋養(yǎng)細(xì)胞腫瘤的臨床療效。方法 以入院病例號為編號,根據(jù)隨機數(shù)字表法,將80名確診為惡性滋養(yǎng)細(xì)胞腫瘤的患者隨機分成兩組,每組40例。對照組給予5-Fu化療;觀察組給予5-Fu聯(lián)合甲氨蝶呤治療。觀察兩組患者治療后血人絨毛膜促性腺激素(HCG)變化、臨床癥狀緩解情況、療效及不良反應(yīng)等指標(biāo)變化情況,探討其臨床治療價值。結(jié)果 治療后,觀察組臨床有效率為97.5%,明顯高于對照組的85.0%,兩組比較差異有統(tǒng)計學(xué)意義(P<0.05)。治療后,觀察組血HCG最高滴定值<10³ mIU/mL患者數(shù)為8例,明顯高于對照組的4例,兩組比較差異有統(tǒng)計學(xué)意義(P<0.05);觀察組血HCG最高滴定值>10⁵ mIU/mL患者數(shù)為6例,明顯低于對照組的18例,兩組比較差異有統(tǒng)計學(xué)意義(P<0.05)。兩組患者不同程度出現(xiàn)白細(xì)胞減少、惡心、嘔吐、口腔潰瘍等不良反應(yīng),但組間差異無統(tǒng)計學(xué)意義。結(jié)論 5-Fu聯(lián)合甲氨蝶呤治療惡性滋養(yǎng)細(xì)胞腫瘤療效確切且安全可靠,值得臨床推廣應(yīng)用。

Objective To investigate the clinical efficacy of 5-fluorouracil (5-Fu) combined with methotrexate in the treatment of malignant trophoblastic tumor. Methods Taking admission number as number, according to the random number table, 80 patients diagnosed as malignant tumor were randomly divided into two groups, 40 cases in each group. Patients in control group were treated with 5-Fu chemotherapy; Patients in observation group were treated with 5-Fu combined with methotrexate. The changes of blood HCG, clinical symptoms, efficacy, and adverse reactions of two groups of patients after treatment were observed. Results After treatment, the clinical effective rate of observation group (97.5%) was significantly higher than that in the control group (85%) (P<0.05). After treatment, the number of patients with the highest HCG value of blood less than 10³ mIU/mL in observation group (8 cases) were significantly higher than the control group (4 cases) (P<0.05); The number of patients with the highest HCG value of blood more than 10⁵ mIU/mL in the observation group (6 cases) was significantly lower than that in the control group (18 cases) (P<0.05). There were different degree of adverse reactions in patients with leukopenia, nausea, vomiting, oral ulcer, but no significant difference between the groups. Conclusion 5-Fu combined with methotrexate is effective and safe in the treatment of malignant tumor. It is worthy of clinical application.